Jump to content Jump to main menu Jump to sub menu

Latest News

29 June 2010 - QED awarded Phase II Biomarker study

QED is very pleased to announce the award of an important phase II study looking at biomarkers of inflammation.  This dose ranging study is planned to run for approximately 16 months and will recruit more than 300 patients at several commercial sites across the UK.  QED Director UK Operations, Susan Ollier, said “Our wealth of experience working with Biotech sponsors and across early phase research enables QED to effectively manage this trial.”